N@N

50.67% Of All NASDAQ Trading Friday Was Short Selling. IMOS, ENCO, CRBC, MBRX, WRLD, MTSN Highest % Of Daily Trading Volume Sh

^{Published on 2009-10-04 20:06:44, Last Modified on 2010-12-22 14:50:59 - WOPRAI}
 

October 5, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Friday, October 2nd, 2009 and come to the following statistical conclusions. There were 6,689 stocks with daily short volume reported and total NASDAQ trading volume of 1,996,265,643 shares. Total Daily Short Volume was 1,011,545,028 shares. 50.67% of all trading on the NASDAQ Friday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. ChipMOS Technologies (NASDAQ: IMOS), Encorium Group (NASDAQ: ENCO), Citizens Republic Bancorp (NASDAQ: CRBC), Metabasis Therapeutics (NASDAQ: MBRX), World Acceptance Corp (NASDAQ: WRLD) and Mattson Technology (NASDAQ: MTSN). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20091002 IMOS 221,773 251,355 Q 88.23%

20091002 ENCO 103,340 117,420 Q 88.01%

20091002 CRBC 5,208,740 6,346,438 Q 82.07%

20091002 MBRX 61,192 76,092 Q 80.42%

20091002 WRLD 140,275 179,805 Q 78.02%

20091002 MTSN 156,989 201,933 Q 77.74%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

ChipMOS TECHNOLOGIES (Bermuda), LTD. (NASDAQ: IMOS), together with its subsidiaries, provides testing and assembly services for liquid crystal display (LCD), and other flat-panel display driver semiconductors and advanced memory and mixed-signal products in Taiwan, Mainland China, Japan, Korea, Hong Kong, and the United States. It provides a range of back-end testing services for memory and mixed-signal semiconductors, which include engineering testing, wafer probing, laser repairing, burn-in testing, top marking, final testing, and final inspection and packing. The companya�s assembly services comprise wafer lapping, die saw, die attach, wire bonding, molding, marking, dejunking and trimming, electrical plating, ball mount and reflow, and forming/singulation. It also offers leadframe-based packages consisting of thin small outline packages and organic substrate-based packages, including fine-pitch ball grid array packages for memory and mixed-signal semiconductors; and gold bumping, testing, and assembly services for LCD and other flat-panel display driver semiconductors. In addition, the company provides memory module manufacturing; drop shipment services; and software engineering services, including test program development, conversion and optimization, related hardware design. Its tested and assembled products are used in personal computers; graphics applications; communications equipment; and consumer electronic products and display applications. The company was founded in 1986 and is based in Hsinchu, Taiwan.

Encorium Group, Inc. (NASDAQ: ENCO) designs and manages clinical trials for pharmaceutical, biotechnology, and medical device industries primarily in Europe. The companya�s clinical research and development services supporting Phase I through Phase IV clinical trials include data management, such as CRF review and tracking, data entry, clinical/statistical reports, and writing manuscripts for publication; and biostatistics for the use of professionals to develop and review protocols, design analysis plans, and report formats in various phases of drug development. Its services also include strategic trial planning; project management; medical writing; quality assurance and compliance, such as investigator audits, pre-submission protocol compliance audits, and GCP audits; outsourcing clinical staff; and clinical trials management comprising case report form design, investigator recruitment, patient enrollment, and study monitoring and data collection. In addition, Encoriuma�s services include study protocol design; medical and regulatory affairs, such as regulatory strategy formulation, new drug and biologic license application document preparation and review, and quality assurance and liaison; pharmacovigilance; compliance and medical report writing; patient registries; and medical device certification. It also licenses Oracle Clinical and Datafax as its clinical trials management systems. Encorium offers clinical trial services in various therapeutic areas, such as cardiovascular, nephrology, endocrinology/metabolism, hematology, diabetes, neurology, oncology, immunology, vaccines, infectious diseases, gastroenterology, dermatology, hepatology, rheumatology, urology, ophthalmology, womena�s health, and respiratory medicine. It was formerly known as Covalent Group, Inc. and changed its name to Encorium Group, Inc. in October 2006 in connection with the acquisition of Remedium Oy. The company was founded in 1989 and is headquartered in Wayne, Pennsylvania.

Citizens Republic Bancorp, Inc. (NASDAQ: CRBC) operates as the holding company for Citizens Bank and F&M Banka"Iowa, which provide banking and financial services to individuals and businesses in Michigan, Wisconsin, Ohio, Iowa, and Indiana. The company operates in three divisions: Specialty Commercial, Regional Banking, and Wealth Management. The Specialty Commercial division provides lending, depository, and related financial services to commercial real estate developers, owners of multi-unit commercial properties, middle-market companies, and local governments and municipalities. It offers commercial mortgages, real estate construction lending, term loans, revolving credit arrangements, inventory and accounts receivable financing, and letters of credit; and noncredit services, including deposit accounts, treasury management, corporate cash management, international banking services, advice and assistance in the placement of securities, and financial planning. The Regional Banking division provides a range of lending, depository, and other related financial services to businesses and individual consumers. This division offers direct loans, home equity loans and lines of credit, and residential mortgage loans, as well as checking, savings, and money market accounts; debit and credit cards; ATM network services; certificates of deposit; and fixed and variable annuities. The Wealth Management division offers asset management, financial planning, estate settlement and administration, and credit and deposit products and services, as well as trust and investment services. This division also offers retail mutual funds and other securities, variable and fixed annuities, personal disability and life insurance products, and brokerage services. As of December 31, 2008, the company operated 233 offices and 266 ATM locations. Citizens Republic Bancorp, Inc. was founded in 1871 and is based in Flint, Michigan.

Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, engages in the discovery, development, and commercialization of novel drugs targeting the liver and liver pathways. Its product pipeline includes clinical-stage product candidates and advanced discovery programs for the treatment of metabolic diseases, such as diabetes and hyperlipidemia. The companya�s product candidates under development comprise MB07811, which is in Phase II clinical trials for the treatment of hyperlipidemia; and MB07803, which is in Phase II clinical trials for the treatment of type 2 diabetes. Its metabolic disease advanced discovery programs consist of AMPK, a metabolic disease program focusing on the development of drug candidates for the treatment of type 2 diabetes and other metabolic diseases; Glucagon Antagonist, a program focusing on identifying orally bioavailable glucagon antagonists for the treatment of type 2 diabetes; and TR agonist, a second-generation program to identify drug candidates for the treatment of hyperlipidemia. It has collaborative research and development agreements with Roche; Merck & Co.; Idenix Pharmaceuticals, Inc.; Daiichi Sankyo Company, Ltd.; Valeant Pharmaceuticals International; and Schering Corporation. The company was founded in 1997 and is based in La Jolla, California.

World Acceptance Corporation (NASDAQ: WRLD) engages in small-loan consumer finance business. It offers short-term small loans, medium-term larger loans, related credit insurance, and ancillary products and services, as well as loans standardized by amount and maturity. The company also offers income tax return preparation services and access to refund anticipation loans. In addition, it markets and sells credit life, credit accident and health, credit property, and unemployment insurance products; markets automobile club memberships to its borrowers; and reinsures credit insurance. Further, the company, through its subsidiary, ParaData Financial Systems, provides data processing systems; and markets computer software and related services to financial services companies. It serves individuals with limited access to consumer credit from banks, savings and loans, other consumer finance businesses, and credit card lenders. As of March 31, 2009, the company has 944 offices in South Carolina, Georgia, Texas, Oklahoma, Louisiana, Tennessee, Illinois, Missouri, New Mexico, Kentucky, Alabama, and Mexico. World Acceptance Corporation was founded in 1962 and is headquartered in Greenville, South Carolina.

Mattson Technology, Inc. (NASDAQ: MTSN) designs, manufactures, and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits for the semiconductor manufacturing industry worldwide. It offers dry strip and rapid thermal processing equipment, and isotropic and low aspect ratio reactive ion. The companya�s dry strip product line includes Suprema strip tool that creates gaseous chemistries, or plasmas, to which the wafer is exposed to remove mask films and residues; and Alpine, a low temperature dry strip system. Its rapid thermal processing (RTP) product line comprises the 2900 for 200 mm applications, the Helios RTP system for 300 mm anneal applications, and the Atmos rapid thermal oxidation system for 300 mm advanced oxidation applications. The companya�s isotropic and low aspect ratio reactive ion removes patterned material from the surface of a wafer to create the device structures. In addition, it offers plasma-based etching systems that include Aspen III LiteEtch systems for isotropic etching applications; and Nexion anisotropic etch systems for various etch applications. The company sells its products directly, as well as through distribution agreements to foundries, and memory and logic device manufacturers. Mattson Technology, Inc. was founded in 1988 and is headquartered in Fremont, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net